Journey Medical Corporation DERM Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Accutane | $12.54M-27.3% | $12.88M-33.6% | $13.69M-33.5% | $14.92M-30.5% | $17.24M-19.2% | |
| Emrosi | $18.93M— | $14.75M— | —— | —— | —— | |
| Foam Franchise Products Amzeeq Zilxi | $5.38M— | $5.86M— | $5.92M— | $6.71M— | —— | |
| Other Legacy | $2.29M-35.0% | $2.74M-30.9% | $3.28M-17.5% | $3.53M-22.2% | $3.52M-31.9% | |
| Qbrexza | $24.88M-1.5% | $25.02M-0.4% | $25.15M-6.2% | $25.37M+1.1% | $25.26M-4.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Journey Medical Corporation break its business down?
- Journey Medical Corporation (DERM) reports revenue by product across 5 parts — Accutane, Emrosi, Foam Franchise Products Amzeeq Zilxi, Other Legacy and Qbrexza. Each is extracted from the segment footnotes and tracked over time.
- Where does Journey Medical Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Journey Medical Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
